Related Experiment Video
Updated: Oct 18, 2025

Author Spotlight: Advancing Pathogen Detection and Disease Assessment in Real-Time Using M-ROSE
Published on: March 1, 2024
Outbreak of Mucormycosis in Coronavirus Disease Patients, Pune, India
Abstract:
We provide an overview of the epidemiology and clinical course of mucormycosis in the coronavirus disease (COVID-19) pandemic era. We conducted a retrospective chart review of 178 patients with clinical or diagnostic, endoscopically or histopathologically confirmed rhino-sino-orbital or cerebral mucormycosis after COVID-19 treatment during the second wave of COVID-19 in Pune, India. Median time to symptom onset from COVID-19 detection was 28 days. Moderate or severe COVID-19 was seen in 73% of patients and diabetes in 74.2%. A total of 52.8% received steroids. Eschar over or inside the nose was seen in 75%, but baseline clinical and laboratory parameters were mostly unremarkable. Bone penetration was present in ≈90% of cases, 30% had soft-tissue swelling of the pterygopalatine fossa and 7% had cavernous sinus thrombosis, and 60% had multifocal mucormycosis. Of the 178 study cases, 151 (85%) underwent surgical debridement. Twenty-six (15%) died, and 16 (62%) of those had multifocal mucormycosis.
Insights
Mucormycosis, a fungal infection, surged during COVID-19, particularly in diabetic patients treated with steroids. Early diagnosis and surgical intervention are crucial for managing this severe rhino-orbital-cerebral disease.
Area of Science:
- Infectious Diseases
- Ophthalmology
- Otolaryngology
- Neurosurgery
Background:
- The coronavirus disease (COVID-19) pandemic has been associated with a rise in mucormycosis cases.
- Mucormycosis, a serious fungal infection, poses a significant threat, especially in immunocompromised individuals.
Purpose of the Study:
- To investigate the epidemiology and clinical characteristics of mucormycosis in patients following COVID-19 treatment.
- To identify risk factors and outcomes associated with rhino-sino-orbital and cerebral mucormycosis during the pandemic.
Main Methods:
- Retrospective chart review of 178 patients with confirmed mucormycosis post-COVID-19 treatment.
- Data collection included patient demographics, COVID-19 severity, comorbidities, treatment, clinical presentation, and outcomes.
Main Results:
- The median time from COVID-19 detection to symptom onset was 28 days.
- 73% of patients had moderate to severe COVID-19, and 74.2% had diabetes; 52.8% received steroids.
- Nasal eschar was present in 75%, bone penetration in ~90%, and multifocal disease in 60%. Mortality was 15%, with 62% of deaths occurring in multifocal cases.
Conclusions:
- Mucormycosis is a significant complication in COVID-19 patients, particularly those with diabetes and steroid use.
- Aggressive surgical debridement is essential, and multifocal disease portends a poor prognosis.
Related Concept Videos
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pulmonary Tuberculosis III
The first classification is based on the development of the disease, and it includes the following categories:
Pulmonary Tuberculosis IV
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Pulmonary Tuberculosis II
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Fungal Group Zygomycota

